A citation-based method for searching scientific literature

Ferran Nadeu, Romina Royo, Guillem Clot, Martí Duran-Ferrer, Alba Navarro, Silvia Martín, Junyan Lu, Thorsten Zenz, Tycho Baumann, Pedro Jares, Xose S Puente, José I Martín-Subero, Julio Delgado, Elías Campo. Blood 2021
Times Cited: 6







List of co-cited articles
80 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


A B-cell epigenetic signature defines three biologic subgroups of chronic lymphocytic leukemia with clinical impact.
A C Queirós, N Villamor, G Clot, A Martinez-Trillos, M Kulis, A Navarro, E M M Penas, S Jayne, A Majid, J Richter,[...]. Leukemia 2015
79
66

Non-coding recurrent mutations in chronic lymphocytic leukaemia.
Xose S Puente, Silvia Beà, Rafael Valdés-Mas, Neus Villamor, Jesús Gutiérrez-Abril, José I Martín-Subero, Marta Munar, Carlota Rubio-Pérez, Pedro Jares, Marta Aymerich,[...]. Nature 2015
500
66

Mutations driving CLL and their evolution in progression and relapse.
Dan A Landau, Eugen Tausch, Amaro N Taylor-Weiner, Chip Stewart, Johannes G Reiter, Jasmin Bahlo, Sandra Kluth, Ivana Bozic, Mike Lawrence, Sebastian Böttcher,[...]. Nature 2015
565
66

IGLV3-21*01 is an inherited risk factor for CLL through the acquisition of a single-point mutation enabling autonomous BCR signaling.
Palash C Maity, Mayas Bilal, Marvyn T Koning, Marc Young, Cornelis A M van Bergen, Valerio Renna, Antonella Nicolò, Moumita Datta, Eva Gentner-Göbel, Rob S Barendse,[...]. Proc Natl Acad Sci U S A 2020
19
66

Prognostic impact of prevalent chronic lymphocytic leukemia stereotyped subsets: analysis within prospective clinical trials of the German CLL Study Group (GCLLSG).
Sonia Jaramillo, Andreas Agathangelidis, Christof Schneider, Jasmin Bahlo, Sandra Robrecht, Eugen Tausch, Johannes Bloehdorn, Manuela Hoechstetter, Kirsten Fischer, Barbara Eichhorst,[...]. Haematologica 2020
13
50

Extended follow-up and impact of high-risk prognostic factors from the phase 3 RESONATE study in patients with previously treated CLL/SLL.
J R Brown, P Hillmen, S O'Brien, J C Barrientos, N M Reddy, S E Coutre, C S Tam, S P Mulligan, U Jaeger, P M Barr,[...]. Leukemia 2018
147
50

Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial.
Jeff P Sharman, Miklos Egyed, Wojciech Jurczak, Alan Skarbnik, John M Pagel, Ian W Flinn, Manali Kamdar, Talha Munir, Renata Walewska, Gillian Corbett,[...]. Lancet 2020
137
50

Stereotyped B-cell receptors in one-third of chronic lymphocytic leukemia: a molecular classification with implications for targeted therapies.
Andreas Agathangelidis, Nikos Darzentas, Anastasia Hadzidimitriou, Xavier Brochet, Fiona Murray, Xiao-Jie Yan, Zadie Davis, Ellen J van Gastel-Mol, Cristina Tresoldi, Charles C Chu,[...]. Blood 2012
269
50

Prognostic and predictive impact of genetic markers in patients with CLL treated with obinutuzumab and venetoclax.
Eugen Tausch, Christof Schneider, Sandra Robrecht, Can Zhang, Anna Dolnik, Johannes Bloehdorn, Jasmin Bahlo, Othman Al-Sawaf, Matthias Ritgen, Anna-Maria Fink,[...]. Blood 2020
34
50

Genomic aberrations and survival in chronic lymphocytic leukemia.
H Döhner, S Stilgenbauer, A Benner, E Leupolt, A Kröber, L Bullinger, K Döhner, M Bentz, P Lichter. N Engl J Med 2000
50

Ibrutinib-Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia.
Tait D Shanafelt, Xin V Wang, Neil E Kay, Curtis A Hanson, Susan O'Brien, Jacqueline Barrientos, Diane F Jelinek, Esteban Braggio, Jose F Leis, Cong C Zhang,[...]. N Engl J Med 2019
251
50


Complex karyotypes and KRAS and POT1 mutations impact outcome in CLL after chlorambucil-based chemotherapy or chemoimmunotherapy.
Carmen Diana Herling, Marion Klaumünzer, Cristiano Krings Rocha, Janine Altmüller, Holger Thiele, Jasmin Bahlo, Sandra Kluth, Giuliano Crispatzu, Marco Herling, Joanna Schiller,[...]. Blood 2016
79
50

Mutations of NOTCH1 are an independent predictor of survival in chronic lymphocytic leukemia.
Davide Rossi, Silvia Rasi, Giulia Fabbri, Valeria Spina, Marco Fangazio, Francesco Forconi, Roberto Marasca, Luca Laurenti, Alessio Bruscaggin, Michaela Cerri,[...]. Blood 2012
302
50

Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial.
Stephan Stilgenbauer, Andrea Schnaiter, Peter Paschka, Thorsten Zenz, Marianna Rossi, Konstanze Döhner, Andreas Bühler, Sebastian Böttcher, Matthias Ritgen, Michael Kneba,[...]. Blood 2014
327
50

Prognostic impact of prevalent chronic lymphocytic leukemia stereotyped subsets: analysis within prospective clinical trials of the German CLL Study Group (GCLLSG).
Sonia Jaramillo, Andreas Agathangelidis, Christof Schneider, Jasmin Bahlo, Sandra Robrecht, Eugen Tausch, Johannes Bloehdorn, Manuela Hoechstetter, Kirsten Fischer, Barbara Eichhorst,[...]. Haematologica 2019
12
50

Epigenomic analysis detects widespread gene-body DNA hypomethylation in chronic lymphocytic leukemia.
Marta Kulis, Simon Heath, Marina Bibikova, Ana C Queirós, Alba Navarro, Guillem Clot, Alejandra Martínez-Trillos, Giancarlo Castellano, Isabelle Brun-Heath, Magda Pinyol,[...]. Nat Genet 2012
372
50

Higher-order connections between stereotyped subsets: implications for improved patient classification in CLL.
Andreas Agathangelidis, Anastasia Chatzidimitriou, Katerina Gemenetzi, Veronique Giudicelli, Maria Karypidou, Karla Plevova, Zadie Davis, Xiao-Jie Yan, Sabine Jeromin, Christof Schneider,[...]. Blood 2021
14
50

Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia.
Philip A Thompson, Constantine S Tam, Susan M O'Brien, William G Wierda, Francesco Stingo, William Plunkett, Susan C Smith, Hagop M Kantarjian, Emil J Freireich, Michael J Keating. Blood 2016
313
33

SF3B1 mutations correlated to cytogenetics and mutations in NOTCH1, FBXW7, MYD88, XPO1 and TP53 in 1160 untreated CLL patients.
S Jeromin, S Weissmann, C Haferlach, F Dicker, K Bayer, V Grossmann, T Alpermann, A Roller, A Kohlmann, T Haferlach,[...]. Leukemia 2014
161
33

Fixed Duration of Venetoclax-Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia Eradicates Minimal Residual Disease and Prolongs Survival: Post-Treatment Follow-Up of the MURANO Phase III Study.
Arnon P Kater, John F Seymour, Peter Hillmen, Barbara Eichhorst, Anton W Langerak, Carolyn Owen, Maria Verdugo, Jenny Wu, Elizabeth A Punnoose, Yanwen Jiang,[...]. J Clin Oncol 2019
145
33

Venetoclax Plus Rituximab in Relapsed Chronic Lymphocytic Leukemia: 4-Year Results and Evaluation of Impact of Genomic Complexity and Gene Mutations From the MURANO Phase III Study.
Arnon P Kater, Jenny Qun Wu, Thomas Kipps, Barbara Eichhorst, Peter Hillmen, James D'Rozario, Sarit Assouline, Carolyn Owen, Tadeusz Robak, Javier de la Serna,[...]. J Clin Oncol 2020
36
33

International prognostic score for asymptomatic early-stage chronic lymphocytic leukemia.
Adalgisa Condoluci, Lodovico Terzi di Bergamo, Petra Langerbeins, Manuela A Hoechstetter, Carmen D Herling, Lorenzo De Paoli, Julio Delgado, Kari G Rabe, Massimo Gentile, Michael Doubek,[...]. Blood 2020
32
33

Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL.
Jennifer A Woyach, Amy S Ruppert, Nyla A Heerema, Weiqiang Zhao, Allison M Booth, Wei Ding, Nancy L Bartlett, Danielle M Brander, Paul M Barr, Kerry A Rogers,[...]. N Engl J Med 2018
364
33

Dissection of subclonal evolution by temporal mutation profiling in chronic lymphocytic leukemia patients treated with ibrutinib.
Ambrus Gángó, Donát Alpár, Bence Galik, Dóra Marosvári, Richárd Kiss, Viktória Fésüs, Dóra Aczél, Ediz Eyüpoglu, Noémi Nagy, Ákos Nagy,[...]. Int J Cancer 2020
17
33

Final Results of a Randomized, Phase III Study of Rituximab With or Without Idelalisib Followed by Open-Label Idelalisib in Patients With Relapsed Chronic Lymphocytic Leukemia.
Jeff P Sharman, Steven E Coutre, Richard R Furman, Bruce D Cheson, John M Pagel, Peter Hillmen, Jacqueline C Barrientos, Andrew D Zelenetz, Thomas J Kipps, Ian W Flinn,[...]. J Clin Oncol 2019
99
33

Molecular prediction of durable remission after first-line fludarabine-cyclophosphamide-rituximab in chronic lymphocytic leukemia.
Davide Rossi, Lodovico Terzi-di-Bergamo, Lorenzo De Paoli, Michaela Cerri, Guido Ghilardi, Annalisa Chiarenza, Pietro Bulian, Carlo Visco, Francesca R Mauro, Fortunato Morabito,[...]. Blood 2015
158
33

Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia.
Xose S Puente, Magda Pinyol, Víctor Quesada, Laura Conde, Gonzalo R Ordóñez, Neus Villamor, Georgia Escaramis, Pedro Jares, Sílvia Beà, Marcos González-Díaz,[...]. Nature 2011
33

Chronic lymphocytic leukaemia: from genetics to treatment.
Francesc Bosch, Riccardo Dalla-Favera. Nat Rev Clin Oncol 2019
65
33

Evolution and impact of subclonal mutations in chronic lymphocytic leukemia.
Dan A Landau, Scott L Carter, Petar Stojanov, Aaron McKenna, Kristen Stevenson, Michael S Lawrence, Carrie Sougnez, Chip Stewart, Andrey Sivachenko, Lili Wang,[...]. Cell 2013
919
33

Genomic arrays identify high-risk chronic lymphocytic leukemia with genomic complexity: a multi-center study.
Alexander C Leeksma, Panagiotis Baliakas, Theodoros Moysiadis, Anna Puiggros, Karla Plevova, Anne-Marie Van der Kevie-Kersemaekers, Hidde Posthuma, Ana E Rodriguez-Vicente, Anh Nhi Tran, Gisela Barbany,[...]. Haematologica 2021
16
33

Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial.
Kirsten Fischer, Jasmin Bahlo, Anna Maria Fink, Valentin Goede, Carmen Diana Herling, Paula Cramer, Petra Langerbeins, Julia von Tresckow, Anja Engelke, Christian Maurer,[...]. Blood 2016
390
33

Single-agent ibrutinib in treatment-naïve and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience.
Susan O'Brien, Richard R Furman, Steven Coutre, Ian W Flinn, Jan A Burger, Kristie Blum, Jeff Sharman, William Wierda, Jeffrey Jones, Weiqiang Zhao,[...]. Blood 2018
237
33

Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia.
R N Damle, T Wasil, F Fais, F Ghiotto, A Valetto, S L Allen, A Buchbinder, D Budman, K Dittmar, J Kolitz,[...]. Blood 1999
33

ASCEND: Phase III, Randomized Trial of Acalabrutinib Versus Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia.
Paolo Ghia, Andrzej Pluta, Malgorzata Wach, Daniel Lysak, Tomas Kozak, Martin Simkovic, Polina Kaplan, Iryna Kraychok, Arpad Illes, Javier de la Serna,[...]. J Clin Oncol 2020
88
33

Ibrutinib for Chronic Lymphocytic Leukemia with TP53 Alterations.
Inhye E Ahn, Xin Tian, Adrian Wiestner. N Engl J Med 2020
27
33

NOTCH1 mutations identify a genetic subgroup of chronic lymphocytic leukemia patients with high risk of transformation and poor outcome.
N Villamor, L Conde, A Martínez-Trillos, M Cazorla, A Navarro, S Beà, C López, D Colomer, M Pinyol, M Aymerich,[...]. Leukemia 2013
126
33

Clinical impact of clonal and subclonal TP53, SF3B1, BIRC3, NOTCH1, and ATM mutations in chronic lymphocytic leukemia.
Ferran Nadeu, Julio Delgado, Cristina Royo, Tycho Baumann, Tatjana Stankovic, Magda Pinyol, Pedro Jares, Alba Navarro, David Martín-García, Sílvia Beà,[...]. Blood 2016
172
33

Prediction of Outcome in Patients With Chronic Lymphocytic Leukemia Treated With Ibrutinib: Development and Validation of a Four-Factor Prognostic Model.
Inhye E Ahn, Xin Tian, David Ipe, Mei Cheng, Maher Albitar, L Claire Tsao, Lei Zhang, Wanlong Ma, Sarah E M Herman, Erika M Gaglione,[...]. J Clin Oncol 2021
25
33

Acquisition of the Recurrent Gly101Val Mutation in BCL2 Confers Resistance to Venetoclax in Patients with Progressive Chronic Lymphocytic Leukemia.
Piers Blombery, Mary Ann Anderson, Jia-Nan Gong, Rachel Thijssen, Richard W Birkinshaw, Ella R Thompson, Charis E Teh, Tamia Nguyen, Zhen Xu, Christoffer Flensburg,[...]. Cancer Discov 2019
162
33

Multiple BCL2 mutations cooccurring with Gly101Val emerge in chronic lymphocytic leukemia progression on venetoclax.
Piers Blombery, Ella R Thompson, Tamia Nguyen, Richard W Birkinshaw, Jia-Nan Gong, Xiangting Chen, Michelle McBean, Rachel Thijssen, Thomas Conway, Mary Ann Anderson,[...]. Blood 2020
45
33

Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia.
T J Hamblin, Z Davis, A Gardiner, D G Oscier, F K Stevenson. Blood 1999
33

Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial.
Othman Al-Sawaf, Can Zhang, Maneesh Tandon, Arijit Sinha, Anna-Maria Fink, Sandra Robrecht, Olga Samoylova, Anna M Liberati, Javier Pinilla-Ibarz, Stephen Opat,[...]. Lancet Oncol 2020
57
33

Cytogenetic complexity in chronic lymphocytic leukemia: definitions, associations, and clinical impact.
Panagiotis Baliakas, Sabine Jeromin, Michalis Iskas, Anna Puiggros, Karla Plevova, Florence Nguyen-Khac, Zadie Davis, Gian Matteo Rigolin, Andrea Visentin, Aliki Xochelli,[...]. Blood 2019
67
33


Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
B Eichhorst, T Robak, E Montserrat, P Ghia, C U Niemann, A P Kater, M Gregor, F Cymbalista, C Buske, P Hillmen,[...]. Ann Oncol 2021
46
33

Geographic patterns and pathogenetic implications of IGHV gene usage in chronic lymphocytic leukemia: the lesson of the IGHV3-21 gene.
Paolo Ghia, Kostas Stamatopoulos, Chrysoula Belessi, Carol Moreno, Stefania Stella, Giuseppe Guida, Ariane Michel, Marta Crespo, Nikolaos Laoutaris, Emili Montserrat,[...]. Blood 2005
153
33

Distinct homotypic B-cell receptor interactions shape the outcome of chronic lymphocytic leukaemia.
Claudia Minici, Maria Gounari, Rudolf Übelhart, Lydia Scarfò, Marcus Dühren-von Minden, Dunja Schneider, Alpaslan Tasdogan, Alabbas Alkhatib, Andreas Agathangelidis, Stavroula Ntoufa,[...]. Nat Commun 2017
50
33

Higher-order immunoglobulin repertoire restrictions in CLL: the illustrative case of stereotyped subsets 2 and 169.
Katerina Gemenetzi, Fotis Psomopoulos, Alejandra A Carriles, Maria Gounari, Claudia Minici, Karla Plevova, Lesley-Ann Sutton, Maria Tsagiopoulou, Panagiotis Baliakas, Kostas Pasentsis,[...]. Blood 2021
5
40

The U1 spliceosomal RNA is recurrently mutated in multiple cancers.
Shimin Shuai, Hiromichi Suzuki, Ander Diaz-Navarro, Ferran Nadeu, Sachin A Kumar, Ana Gutierrez-Fernandez, Julio Delgado, Magda Pinyol, Carlos López-Otín, Xose S Puente,[...]. Nature 2019
59
33


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.